Overview and organizational history
Ibogaine by David Dardashti describes itself as a treatment center and research-oriented program specializing in ibogaine-assisted therapy, with operations dating to 2004 and a primary clinical offering in Playa del Carmen, Mexico.[1] The organization lists a U.S. contact location at 1031 Ives Dairy Rd, Miami, Florida, used for outreach and coordination rather than ibogaine administration due to U.S. legal restrictions on the compound.[2][3] Marketing materials claim experience treating thousands of individuals and emphasize longevity and specialization in ibogaine protocols.[1][4]
Because ibogaine is a Schedule I substance in the United States, treatment is typically pursued in jurisdictions where it is not scheduled, which aligns with this program’s Mexico-based clinical setting.[1][3] Readers seeking broader background on ibogaine can see What Is Ibogaine? Effects, Uses, Risks & Legal Status and Ibogaine Treatment: Evidence, Risks, Protocols & Legality.
Treatment offerings and stated claims
The program advertises personalized ibogaine-assisted protocols for opioid addiction, PTSD, depression, anxiety, and other conditions, sometimes described as covering 30+ disorders in promotional materials.[1] Its website references “dozens of protocols,” use of software/algorithms for dosing and customization, an intensive single-visit format in some cases, and the goal of rapid withdrawal relief for opioid dependence.[1][4] Such claims reflect marketing positions and should be weighed against the broader scientific literature and safety guidelines for ibogaine therapy.[5] For context on specific indications, see Ibogaine for Opioid Addiction: Evidence, Risks & Legality and Ibogaine for PTSD: A Research Overview.
Evidence base and research status
As of the latest review, no peer-reviewed, controlled clinical trials or published outcomes specific to the proprietary “Ibogaine by David Dardashti” protocol were identified in public databases, and the program’s efficacy assertions have not been independently validated in the literature.[1][6] In the broader field, human ibogaine research consists largely of open-label and observational work, with ongoing but still limited clinical trial activity relative to standard treatments for substance use disorders.[5][6] Prospective patients should compare clinic marketing claims to the established evidence for first-line therapies such as buprenorphine, methadone, and naltrexone when evaluating options for opioid use disorder.[7]
Ibogaine pharmacology in brief
Ibogaine is a naturally occurring indole alkaloid derived primarily from the West African shrub Tabernanthe iboga, with its active metabolite noribogaine contributing to pharmacological effects over an extended time course.[8][9] Preclinical and translational literature suggest multi-receptor activity across serotonergic, glutamatergic, and other systems relevant to addiction and mood, although definitive human mechanism–outcome relationships remain under investigation.[5][8] Program claims of “advanced algorithms” for dose personalization should be viewed within this complex and individualized pharmacology, and balanced with rigorous medical screening and monitoring standards recommended by field guidelines.[1][5] For more on mechanisms, see How Ibogaine Works: Mechanisms & Risks and Ibogaine Effects on the Brain.
Safety, risks, and monitoring standards
Ibogaine has documented cardiac risks, notably QTc prolongation and the potential for torsades de pointes, necessitating strict pre-screening, medication review, electrolyte management, and continuous cardiac monitoring in appropriate settings.[5] Clinical guidelines emphasize exclusion criteria such as structural heart disease, long-QT syndromes, uncontrolled seizures, and problematic polypharmacy (e.g., concomitant QT-prolonging and serotonergic agents), alongside 24/7 monitoring capacity and clear emergency protocols.[5] The organization states that it personalizes dosing and conducts medical vetting; prospective patients should verify on-site capabilities, staff credentials, and adverse event reporting practices directly with the clinic.[1][5] For broader safety context, see Ibogaine Side Effects: Risks & Safety and Ibogaine Treatment Centers: Safety, Legality & Choosing One.
Legal and regulatory status
In the United States, ibogaine is a Schedule I controlled substance; manufacture, possession, or dispensing is illegal outside approved research, which constrains any U.S.-based clinical use.[3] The program therefore delivers ibogaine therapy in Mexico, where it is not federally scheduled and private clinics operate under general medical and service regulations, according to the organization’s materials.[1] Individuals considering cross-border care should review applicable laws, travel risks, and follow-up options in their home jurisdiction; see Ibogaine Treatment in Mexico: Legality, Clinics, Safety and Ibogaine Treatment in the United States.
How it compares with standard treatments
For opioid use disorder, medications such as methadone, buprenorphine, and extended-release naltrexone have robust evidence for reducing mortality, overdose, and illicit use, and they are widely recommended as first-line care in regulated systems.[7] By contrast, ibogaine’s evidence base remains preliminary, with limited controlled data and significant safety considerations that require higher-acuity monitoring than most outpatient services provide.[5][6] Patients exploring ibogaine as a detoxification aid sometimes aim to transition to antagonist therapy or psychosocial supports post-treatment; such strategies should be planned with qualified clinicians and anchored in evidence-based care pathways.[7]
Practical considerations and due diligence
Before committing to any ibogaine program, request written details on medical screening (including ECG/QTc and labs), medication washout plans, dosing rationales, continuous monitoring, resuscitation capabilities, and adverse event statistics, and verify provider licensing where applicable.[5] Ask for any published or de-identified outcomes, IRB approvals (if research claims are made), and clarify aftercare coordination for ongoing treatment in your home region.[5][6] For additional guidance, see Ibogaine Clinics: Safety, Legality, Costs & Evidence and How to Get Ibogaine Treatment Safely.